the medical insurance price and personal burden after reimbursement:
At present, the medical insurance has successfully entered the medical insurance, and the price has been reduced from the previous 19,6 yuan to 3,52 yuan per box, with a drop of 82%. After reimbursement by medical insurance, the out-of-pocket payment for taking amitriptyline has become about 3, yuan per month, greatly reducing the economic burden of patients. The scope of payment for medical insurance for amitriptyline is as follows: Adult patients with locally advanced or metastatic non-small cell lung cancer who have progressed during or after treatment with receptor tyrosine kinase inhibitors and have been confirmed to have eg fr t79M mutation.
Amitinib
is a targeted drug against eg fr independently developed in China, the first in China, the second lung cancer in the world, and the third-generation EGFR targeted drug. In March last year, Amitinib was approved for marketing in National Medical Products Administration for the treatment of advanced NSCLC patients with T79M positive fr tki treatment in previous epidemic areas, which is also the first second-line treatment in the world with no progress and PFS survival time of more than one year.
Efficacy of amittinib in the treatment of advanced lung cancer:
A clinical trial involving 244 patients with advanced non-small cell lung cancer in China with EGFR mutation and T79M positive showed that the overall treatment efficiency was 68.9%, the control rate was 93.4%, and the treatment efficiency of patients with asymptomatic brain metastasis reached 61.5%. For patients without brain metastasis, the effective rate reached 72.6%, and the median progression-free survival time reached 12.3 months. Amitinib became the first third-generation eg fr lung cancer targeting drug with a median progression-free survival time of more than one year in second-line treatment in the world.
The third-generation targeted drug of egfr tiki3 developed by Amitinib in China was approved for marketing in China on March 18th, 22, and it was the first third-generation targeted drug made in China. The second-phase clinical study showed that the objective remission rate of PFS in second-line treatment of lung cancer was 68.4%. In addition, the study also found that Amitinib also had brain-entry effect.